Author:
Madny Muzaffaruddin Ahmed,Deshpande Pandurang,Tumuluri Venkat,Borde Parag,Sangana Ramachandra
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmaceutical Science,Agronomy and Crop Science,Ecology,Aquatic Science,General Medicine,Ecology, Evolution, Behavior and Systematics
Reference23 articles.
1. Shoback DG, Gardner D, eds. Chapter 17. Greenspan’s basic & clinical endocrinology (9th ed.). 2011. New York: McGraw-Hill Medical. ISBN 978–0–07–162243–1.
2. Sunkara Gangadhar, Sabo Ron, et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, healthy volunteers. J Clin Pharmacol. 2007;47:1152–8.
3. He Y-L, Sadler BM, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet. 2007;46(9):787–802.
4. He Handan, Tran Phi, et al. Absorption, metabolism, and excretion of [14C] vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metabolism and Disposition. 2009;37(3):536–44.
5. The use of physiologically based pharmacokinetic analyses – biopharmaceutics applications for oral drug product development, manufacturing changes, and controls. Guidance for Industry. Draft Guidance. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), October 2020
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献